Primary Peritoneal Cancer (DBCOND0030277)

Identifiers

Synonyms
Peritoneal Primary Cancer / Primary Peritoneal Cavity Cancer

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00293293
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicinesupportive_careNot Availablecompleted
NCT05281471
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)treatment3recruiting
NCT05739981
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment1 / 2recruiting
NCT02480374
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancertreatment1completed
NCT03393884
Study of IMNN-001 (also Known As GEN-1) with NACT for Treatment of Ovarian Cancer (OVATION 2)treatment1 / 2active_not_recruiting
NCT03635489
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment3completed
NCT05053750
TAME: a Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (zoledronic Acid) in Women with Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment0active_not_recruiting
NCT00562003
Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer PatientsNo drug interventionstreatment1completed
NCT03213964
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Inttreatment1completed
NCT01744821
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal CancerNo drug interventionspreventionNot Availableterminated
NCT04510584
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancertreatment2withdrawn
NCT01652079
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancertreatment2completed
NCT03759587
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancertreatment2completed
NCT01281254
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)treatment3terminated
NCT01220154
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancertreatment1unknown_status
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumorstreatment1recruiting
NCT02606305
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancertreatment1 / 2completed
NCT04029909
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancertreatment1unknown_status
NCT06173037
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNo drug interventionstreatment2recruiting
NCT03759600
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancertreatment2completed
NCT00489359
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancertreatment1 / 2completed
NCT06063070
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancertreatment2not_yet_recruiting
NCT05126342
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPitreatment2not_yet_recruiting
NCT01899599
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancertreatment2completed
NCT02928549
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT01204749
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancertreatment3completed
NCT00520013
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumorstreatment2completed
NCT00059618
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancertreatment1completed
NCT00616941
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT01196741
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancertreatment2 / 3completed
NCT00479817
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancertreatment2completed
NCT00466986
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancertreatment2completed
NCT02324439
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in RemissionNo drug interventionsprevention1completed
NCT04227522
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patientstreatment3active_not_recruiting
NCT02884648
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgerytreatment2recruiting
NCT04590326
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018treatment1 / 2recruiting
NCT00989131
Study of Paclitaxel in Patients With Ovarian Cancertreatment3completed
NCT05574673
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination PhenotypeNo drug interventionsNot AvailableNot Availablerecruiting
NCT01312376
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancertreatment1terminated
NCT05092360
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)treatment3active_not_recruiting
NCT00157560
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian CarcinomaNo drug interventionstreatment2completed
NCT00603460
DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancerother1 / 2withdrawn
NCT05494580
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancertreatment1 / 2recruiting
NCT05086692
A Beta-only IL-2 ImmunoTherapY Studytreatment1 / 2recruiting
NCT03245892
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancertreatment1active_not_recruiting
NCT02012192
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancertreatment1 / 2terminated
NCT01666444
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment2completed
NCT03159572
Homologous Recombination Inquiry Through Ovarian Malignancy InvestigationsNo drug interventionsNot AvailableNot Availablecompleted
NCT04657068
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumorstreatment1 / 2recruiting
NCT01989546
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutationstreatment1 / 2completed
NCT05030246
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancertreatment2unknown_status
NCT00428610
A Study of Chemotherapy Treatment for Patients With Ovarian Cancertreatment2completed
NCT01253681
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancertreatment1completed
NCT04889495
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNot AvailableNot Availablenot_yet_recruiting
NCT04606914
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment2recruiting
NCT03093155
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumabtreatment2completed
NCT05665023
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinomatreatment2recruiting
NCT03189108
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsNo drug interventionsNot AvailableNot Availablecompleted
NCT03507543
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumorstreatment1completed
NCT02121990
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancertreatment1completed
NCT06014190
HS-20089 in Patients With Ovarian Cancer and Endometrial CancerNo drug interventionstreatment2recruiting
NCT05065021
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitortreatment2recruiting
NCT00677079
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT02737787
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancertreatment1completed
NCT02567253
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancertreatment2completed
NCT01219777
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovariantreatment1completed
NCT05329545
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)treatment3terminated
NCT01883297
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1active_not_recruiting
NCT02278783
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancertreatment2terminated
NCT00418093
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinomatreatment2terminated
NCT00314678
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancertreatment2completed
NCT05456685
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancertreatment2active_not_recruiting
NCT00436215
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancertreatment2completed
NCT00226915
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinomatreatment3completed
NCT01306032
Phase II ABT-888 With Cyclophosphamidetreatment2completed
NCT01196559
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancertreatment2completed
NCT02452775
Autologous OC-L Vaccine and Ovarian CancerNo drug interventionstreatment1terminated
NCT00928642
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancertreatment2completed
NCT06545617
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancertreatment1 / 2not_yet_recruiting
NCT00526617
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patientstreatment1completed
NCT03311334
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumorstreatment1 / 2terminated
NCT01880996
Tai-chi / Qi-gong in Patients With Patients With Gynecological MalignanciesNo drug interventionstreatment1 / 2withdrawn
NCT00109096
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapytreatment2completed
NCT01296035
Panitumumab and Gemcitabine in Relapsed Ovarian Cancertreatment2terminated
NCT02435186
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancertreatment2unknown_status
NCT05870748
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1treatment2 / 3recruiting
NCT01663857
A Study LY2228820 for Recurrent Ovarian Cancertreatment1 / 2completed
NCT02948426
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancertreatment1terminated
NCT01570582
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancertreatment2unknown_status
NCT00959582
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)No drug interventionsdiagnostic1completed
NCT04546373
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerNot AvailableNot Availablecompleted
NCT00617773
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT04539327
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO StudyNot AvailableNot Availablecompleted
NCT01312389
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment1 / 2terminated
NCT01237067
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancerstreatment1completed
NCT00799110
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimodtreatment2active_not_recruiting
NCT01146795
Neoadjuvant Therapy for Ovarian Cancertreatment2completed
NCT01339650
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerNo drug interventionstreatment1completed
NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignanciestreatment1completed
NCT01105650
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancertreatment2completed
NCT06617923
Study of Senaparib in Combination With Temozolomidetreatment2not_yet_recruiting
NCT05377996
A Study of XMT-1660 in Participants With Solid TumorsNo drug interventionstreatment1recruiting
NCT00017303
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancertreatment2unknown_status
NCT00014690
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2completed
NCT00012090
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneumtreatment2completed
NCT00004064
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2unknown_status
NCT00003064
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancertreatment1 / 2unknown_status
NCT00036751
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancertreatment2completed
NCT00066651
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumorstreatment1completed
NCT00022347
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2completed
NCT00003345
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT00769405
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancertreatment3completed
NCT00045461
Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment2 / 3unknown_status
NCT00019461
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00006028
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapytreatment2completed
NCT00334893
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancertreatment2completed
NCT00098878
Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment3completed
NCT00023907
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2terminated
NCT00458809
Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancertreatment1completed
NCT00039585
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumortreatment2completed
NCT00003385
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00004115
Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and ChemotherapyNo drug interventionstreatment3unknown_status
NCT00004037
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancertreatment2terminated
NCT00006942
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00023699
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT00601406
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological CancerNo drug interventionstreatmentNot Availableunknown_status
NCT00003136
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancertreatment1 / 2completed
NCT00006041
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerNo drug interventionstreatment1completed
NCT00017017
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancertreatment1 / 2completed
NCT00373217
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment2terminated
NCT00003634
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapytreatment2unknown_status
NCT00004934
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment3completed
NCT00003624
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancersupportive_care2terminated
NCT05538624
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovarytreatment1 / 2terminated
NCT00993616
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatintreatment2completed
NCT00020696
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancertreatment2completed
NCT00093496
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancertreatment2completed
NCT00003358
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT00407758
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT06342986
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancertreatment1recruiting
NCT00096239
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment2completed
NCT00897039
Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT00263822
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancertreatment3completed
NCT00079430
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00005026
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancertreatment1completed
NCT00114166
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00028782
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural CancerdiagnosticNot Availableterminated
NCT00004082
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumorstreatment1completed
NCT00483782
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment3completed
NCT00569673
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancertreatment2completed
NCT00081276
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancertreatment2completed
NCT00003160
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinumtreatment2unknown_status
NCT00002960
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)treatment1completed
NCT00003380
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancertreatment1terminated
NCT00016289
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT00005944
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancertreatment2terminated
NCT00132067
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancertreatment2completed
NCT01100372
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment2unknown_status
NCT00005046
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancertreatment1completed
NCT00075712
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment2 / 3completed
NCT00006812
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancertreatment2terminated
NCT00023712
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT00006112
Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancertreatment2unknown_status
NCT01580410
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendixtreatment2completed
NCT00006981
Immunotoxin Therapy in Treating Patients With Advanced Cancertreatment1completed
NCT00091195
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancertreatment2terminated
NCT00055614
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT00459290
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT00408590
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment1completed
NCT00087087
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT00053833
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2terminated
NCT00031954
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT00574951
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2terminated
NCT00091377
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment1 / 2completed
NCT00005645
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatmenttreatment2withdrawn
NCT00107445
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial CancerNo drug interventionsdiagnostic2completed
NCT00003998
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancertreatment3completed
NCT00429793
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT01402271
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancertreatment1 / 2completed
NCT00003378
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancertreatment1terminated
NCT00303888
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment1terminated
NCT00838656
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2unknown_status
NCT00049556
Gefitinib in Treating Patients With Cervical Cancertreatment2completed
NCT00019552
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT00002600
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancertreatment1completed
NCT00022659
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT00045175
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment1completed
NCT00003670
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancertreatment2completed
NCT00138242
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancertreatment2completed
NCT00693342
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remissiontreatment3withdrawn
NCT00766142
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancertreatment2terminated
NCT00126542
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment2completed
NCT00005836
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapytreatment2completed
NCT00003636
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancertreatment3completed
NCT00041041
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancertreatment2completed
NCT00002717
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancertreatment3completed
NCT00002734
Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancertreatment1completed
NCT00021034
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment1completed
NCT00903396
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancersupportive_care2terminated
NCT00085358
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)treatment1completed
NCT00058435
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment1completed
NCT00006235
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT00003322
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancertreatment3completed
NCT00005025
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancertreatment2unknown_status
NCT00084448
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancertreatment2terminated
NCT00053365
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancertreatment2completed
NCT00004074
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neutreatment1completed
NCT00003382
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancertreatment1terminated
NCT00113373
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancertreatment2completed
NCT00091273
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancertreatment1completed
NCT00003560
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2unknown_status
NCT00004060
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT00002894
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancertreatment3completed
NCT00087191
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerdiagnosticNot Availableterminated
NCT00041080
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment3completed
NCT00003880
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancertreatment2 / 3terminated
NCT00005029
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancertreatment2terminated
NCT00066729
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00872989
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2completed
NCT00086892
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancertreatment2completed
NCT01656044
Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00562640
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)treatment1completed
NCT00072267
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT00006267
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancertreatment2withdrawn
NCT00003967
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00522301
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remissiontreatment2terminated
NCT04630769
FT516 and IL2 With Enoblituzumab for Ovarian Cancertreatment1completed
NCT00028912
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00004012
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00002895
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal CancerNo drug interventionstreatment3completed
NCT00025155
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapytreatment2completed
NCT00003523
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneumtreatment2completed
NCT00305838
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifendiagnostic2unknown_status
NCT00398138
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesotheliomatreatment1completed
NCT00002538
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal CancersNo drug interventionstreatment2completed